GSK plc (GSK) — Q3 2026 Earnings Preview
Key Points
- Consensus expects Q3 2026 revenue of $11,716M (+9% YoY), EBITDA $4,334M, net income $2,774M, EPS $0.55
- Guidance for FY26 sales and operating profit now towards the upper half of the range; EPS in lower half due to Nuvalent acquisition
- Focus areas: Specialty Medicines (notably oncology, respiratory, HIV), new launches (Exdensur, Blenrep, Nuvalent assets), and margin trajectory through dolutegravir LOE
- Q3 2025 was a strong comp: revenue $11,120M (+4% YoY), core operating profit +11%, EPS +12%
- Watch for: Exdensur and Blenrep launch curves post-J-code, payer coverage ramp, oncology pipeline progress, HIV long-acting injectables uptake, and margin impact from cost savings program
- Potential headwinds: Trelegy IRA pricing, GenMed softness, annualization of vaccine bolus, and integration of Nuvalent costs
Table 1: Forward Consensus vs. Prior Year Actuals — Quarterly
| Quarter | Revenue ($M) | YoY Growth | EBITDA ($M) | Net Income ($M) | EPS ($) | Gross Margin (%) |
|---|---|---|---|---|---|---|
| Q3 2026 (E) | 11,716 | +9% | 4,334 | 2,774 | 0.55 | 75.1 |
| Q3 2025 (A) | 11,120 | +4% | 3,987 | 2,542 | 0.55 | 75.7 |
E = consensus estimate; A = actual reported
Table 2: Forward Consensus vs. Prior Year Actuals — Annual
| Fiscal Year | Revenue ($M) | YoY Growth | EBITDA ($M) | Net Income ($M) | EPS ($) | Gross Margin (%) |
|---|---|---|---|---|---|---|
| FY2026 (E) | 44,844 | +2% | 15,170 | 9,534 | 1.70 | 75.2 |
| FY2025 (A) | 43,780 | +12% | 15,132 | 9,276 | 1.87 | 74.7 |
Table 3: Segment/Business Unit Highlights — Q2 2026
| Segment/BU | Q2 2026 Commentary/Trends |
|---|---|
| Specialty Medicines | +14% YoY, driven by Nucala COPD, Cabenuva, Dovato |
| Vaccines | +8% YoY, Arexvy global expansion, Shingrix Europe, Meningitis |
| General Medicines | -9% YoY, Trelegy pricing/abandonment, generic pressure |
| Oncology | Strong pipeline momentum, Nuvalent integration, ADC launches |
| HIV | +10% YoY, long-acting injectables 80% of growth, US +14% |
What to Watch This Quarter
1. Specialty Medicines and Launch Uptake
- Exdensur (depemokimab): J-code went live July 1; >50% insured coverage now. Watch for inflection in new patient starts, especially bio-naive population (70% of severe asthma patients still not on biologics).
- Blenrep: Now approved in 49 countries, reimbursement in Germany/Spain, leading second-line share in UK. US focus is on community setting; expect slow but steady ramp as J-code and REMS coordination mature.
- Nuvalent Assets: Zidesamtinib (JIDEYTRO) approved in ROS1+ NSCLC; neladalkib PDUFA in November for ALK+ NSCLC. Monitor launch execution and early feedback.
2. Oncology Pipeline Progress
- ADC Portfolio: Multiple Phase III starts for Mo-Rez (B7-H4) and Ris-Rez (B7-H3) in gynecologic, lung, and prostate cancers. Recent positive China data for Ris-Rez in small cell lung cancer; global readouts expected.
- Velzatinib (IDRx): First-line and second-line GIST trials recruiting ahead of schedule.
- Jemperli: Endometrial and rectal cancer readouts pending; watch for updates on commercial traction and new indications.
3. HIV Franchise and Long-Acting Injectables
- Cabenuva: 33% sales growth in Q2, 77% of new Rx from competitors. Long-acting injectables now 35% of US HIV sales.
- Pipeline: 3x yearly treatment (QUATTRO) Phase III started, approval targeted for 2028. 2x yearly (VH184 + VH499) Phase IIb ongoing, Phase III start in 2028, approval by end of decade.
- IP Protection: Management confident in patent moat through 2040+ for next-gen regimens; rapid cannibalization of older products expected.
4. Margin Trajectory and Cost Savings
- Accelerate Growth Program: GBP 1.9B annual cost savings by 2029, majority reinvested in R&D, some to margin. Margin guidance: stable to improving through dolutegravir LOE (2028–2030).
- R&D Investment: 20+ Phase III starts in 2026, focus on specialty and oncology.
- SG&A/Productivity: Ongoing drive to reduce SG&A/sales ratio, fund pipeline acceleration.
5. Potential Headwinds
- Trelegy IRA Pricing: Step-down expected in 2027; heavily rebated product, but impact factored into guidance.
- General Medicines Softness: Q2 down 9% YoY; Trelegy abandonment rates elevated but expected to ease in H2.
- Vaccines: Annualization of prior-year bolus (e.g., Arexvy, Shingrix), especially in Europe/Japan; US penetration at 45%, ex-US at 12%.
- Nuvalent Integration: Additional interest expense (~$160M) and cost consolidation may weigh on near-term EPS.
How Did They Report Last Year? (Q3 2025)
- Revenue: $11,120M (+4% YoY)
- EBITDA: $3,987M
- Net Income: $2,542M
- EPS: $0.55
- Gross Margin: 75.7%
- Core Operating Profit: +11%
- EPS Growth: +12%
Q3 2025 was a strong quarter with double-digit profit growth and a solid margin base. This sets up a moderately tough YoY comp for Q3 2026, especially as consensus expects an acceleration to +9% revenue growth.
Summary and Conclusions
- GSK enters Q3 2026 earnings with strong momentum in Specialty Medicines, particularly in respiratory, oncology, and HIV.
- Consensus expects robust top-line growth (+9% YoY) and continued margin strength, with management guiding to the upper half of the FY26 sales and operating profit range.
- Key focus areas are the ramp of Exdensur and Blenrep post-J-code, Nuvalent asset launches, and continued HIV franchise transition to long-acting injectables.
- Potential risks include Trelegy IRA pricing, GenMed softness, vaccine annualization, and integration costs from Nuvalent.
- Q3 2025 was a strong comp, so investors should watch for evidence that new launches and pipeline acceleration can sustain or exceed the expected growth trajectory.
- Margin delivery and cost savings execution will be closely scrutinized, especially as R&D investment ramps and the company navigates the dolutegravir LOE period.
Most Important Factors to Watch When GSK Reports Next
| Factor | Why It Matters | What to Watch For |
|---|---|---|
| Exdensur (depemokimab) ramp | Key new launch, 6-month dosing, large bio-naive pool | Uptake post-J-code, payer coverage, new patient mix |
| Blenrep adoption | Community MM market, REMS complexity, global rollout | US/UK/Europe trends, 2nd/3rd line share, feedback |
| Nuvalent asset launches | Precision oncology, late-stage, large TAM | Early sales, launch execution, regulatory updates |
| HIV long-acting injectables | Franchise transition, IP protection, market share | Cabenuva/Apretude growth, pipeline progress |
| Margin/cost savings delivery | Guidance: stable to improving margin through LOE | SG&A leverage, R&D spend, Accelerate Growth update |
| Trelegy/GenMed headwinds | IRA pricing, generic pressure, segment drag | YoY trends, abandonment rates, mitigation actions |
| Vaccine performance | Shingrix/Arexvy annualization, ex-US growth | Penetration rates, new indications, pricing signals |
| Oncology pipeline progress | ADCs, velzatinib, Jemperli, B7-H3/H4, global trials | Phase III starts, data readouts, regulatory filings |
Conclusion:
GSK's Q3 2026 report will be a key test of its ability to deliver on accelerated growth targets, execute major new launches, and maintain margin discipline amid a shifting portfolio and external headwinds. The most important signals will be the pace of new product uptake (especially Exdensur and Blenrep), continued HIV franchise transformation, and evidence that cost savings and productivity initiatives are supporting both R&D investment and profitability. Investors should expect detailed commentary on launch curves, payer access, pipeline milestones, and the evolving margin outlook through the dolutegravir LOE period.
